Hims & Hers Health has delivered a very large 3 year gain for shareholders, yet the latest valuation work suggests the stock still trades at a discount to its estimated intrinsic value. With fresh headlines around AI in healthcare, peptide therapies and regulatory scrutiny, the big question for investors is how much of that story is already in the price.

• The stock has returned about 396% over the past 3 years, which puts a lot of focus on whether the current share price can still be justified by future cash flows.
• Plans to expand into peptide therapies and build AI driven healthcare services may support long term growth expectations, while the ongoing FTC lawsuit and related investigations highlight legal and reputational risks that can weigh on the valuation.
• On Simply Wall St's broader checks, Hims & Hers Health screens as undervalued in 4 of 6 areas, which points to a mixed picture rather than an obvious bargain or clear overpricing.

For investors, the debate is whether the current discount to the Discounted Cash Flow (DCF) based intrinsic value gives enough margin of safety given the recent share price run and the company specific risks.

Is Hims & Hers Health a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here projects what Hims & Hers Health might generate for shareholders based on future free cash flows. On the latest twelve month numbers, the company produced free cash flow of about $89.9 million, and the model assumes growing cash flows from this base. That stream is then discounted back to today using a 2 stage Free Cash Flow to Equity approach.

On these assumptions, the DCF points to an estimated intrinsic value of about $65.57 per share, which is above the current share price and implies the stock screens as roughly 48.5% undervalued. The ongoing FTC privacy lawsuit helps explain why the market currently prices Hims & Hers Health below what this cash flow model supports, as legal and regulatory outcomes can weigh heavily on sentiment even when cash generation remains positive.

Overall, the DCF work suggests Hims & Hers Health stock appears undervalued relative to its projected cash flows.

Our Discounted Cash Flow (DCF) analysis suggests Hims & Hers Health is undervalued by 48.5%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.

Does Hims & Hers Health Look Undervalued on Sales?

P/S is often a useful cross check for Hims & Hers Health because the business is still focused on scaling its revenue base. The stock currently trades on a P/S ratio of about 3.1x, which is above the broader Healthcare industry average of about 1.5x but below the peer group average of roughly 4.6x.

On Simply Wall St's fair multiple framework, a P/S ratio of around 5.5x would be more in line with Hims & Hers Health's profile, including its growth outlook, margins, size and risk factors. That is higher than the current 3.1x, which indicates the market is assigning a discount relative to what this model implies, even after the strong share price performance and the attention around AI and peptide therapies.

On the P/S multiple, Hims & Hers Health stock appears undervalued relative to both peers and its modelled fair ratio.

The Hims & Hers Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Hims & Hers Health build on this valuation work and set out the specific assumptions on growth, margins and earnings that would need to play out for the stock to be worth significantly more or less than today. These Narratives sit on the company’s Community page. Where a ratio or model offers a single number, Narratives break that into clear future conditions so you can watch how those assumptions hold up over time.

Community views on Hims & Hers Health are far apart, with some investors seeing a multi year growth engine and others focused on GLP 1 and margin risk.

Bull case: 80% undervalued

"Latest news of investments (Ohio facility expansion), acquisitions (YourBio, Livewell, GRAIL Inc. stake, Eucalyptus) and category expansion (Hims TRT, Hers Menopause, Labs) reflects high confidence in demand for new offerings..."

Bear case: 19% overvalued

"Heavy dependence on growth segments and international expansion exposes the company to regulatory, operational, and margin risks, potentially resulting in revenue volatility and compressed profitability..."

Do you think there's more to the story for Hims & Hers Health? Head over to our Community to see what others are saying!

The Bottom Line

On the numbers, Hims & Hers Health screens as undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and the P/S multiple checks, which is unusual after such a very large 3 year move. That discount exists alongside clear legal and regulatory risks, so it is not a simple mispricing story.

For you as an investor, the key question is whether current cash generation and future margin potential ultimately outweigh the privacy and regulatory overhang. The crux of the bull versus bear debate is whether that discount reflects a genuine opportunity or whether the market is correctly pricing the risk that earnings quality and growth expectations prove too optimistic.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.